Case Studies: CASE TWO

Lauren S. Schlesselman, PharmD
Published Online: Wednesday, June 1, 2005

MC presents to her physician's office for a routine checkup. She admits to the physician that she has been experiencing worsening asthma symptoms.

MC has a long history of asthma and congestive heart failure. She is currently taking digoxin 0.125 mg daily. MC is not currently using any medications for her asthma. The physician becomes concerned that MC's digoxin level may be low. He orders a digoxin level and metabolic panel screen. The digoxin level is reported as 0.3 ng/mL. All results in the metabolic panel are within normal limits.

The physician stresses the importance of adhering to her medication therapies. Although MC agrees to take her digoxin, the physician asks her to return in 7 to 10 days for another digoxin level screen. He also starts her on an albuterol inhaler that she can use only when she feels symptomatic.

When the results of the second set of blood work are returned, the digoxin level has increased to 1.0 ng/mL. Unfortunately, MC's serum potassium level is reported as 2.5 mEq/L.

The physician is unsure why MC's potassium level has suddenly dropped. MC denies doing anything differently other than using that "crazy puffer thing for my breathing" and taking her digoxin. What possible cause exists for MC's hypokalemia?

Dr. Schlesselman is a clinical pharmacist based in Niantic, Conn.

Click Here For The Answer -----------> [-]

MC's recent albuterol use is the likely cause of her sudden drop in serum potassium. Albuterol causes potassium to shift from plasma to the intracellular compartment, causing serum levels to decrease. Plasma levels will return to normal if albuterol therapy is discontinued. Unfortunately, MC's risk of digoxin cardiac toxicity is increased with hypokalemia. If she is going to use albuterol routinely, her potassium levels should be monitored closely and treated when levels are extremely low.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues